Key Takeaways from the RGX-314 Phase I/IIa Clinical Trial for Wet AMD (Cohorts 1-5) Jeffrey Heier, MD Peter Campochiaro, MD, Allen Ho, MD, Albert Maguire, MD, David M. Brown, MD, Robert Avery, MD, Dante Pieramici, MD, Sz

for Wet AMD (Cohorts 1-5) Jeffrey Heier, MD Peter Campochiaro, MD, Allen Ho, MD, Albert Maguire, MD, David M. Brown, MD, Robert Avery, MD, Dante Pieramici, MD, Szilard Kiss, MD, Arshad Khanani, MD, Charles Wykoff, MD Samir Patel, MD, Keunpyo Kim,

PhD, Darin Curtiss, PharmD, Stephen Pakola, MD, Sherri Van Everen, PharmD AAO Retina Subspecialty Days 10/11/2019Exhibit 99.1 Key Takeaways from the RGX-314 Phase I/IIa Clinical Trial for Wet AMD (Cohorts 1-5) Jeffrey Heier, MD Peter Campochiaro,

MD, Allen Ho, MD, Albert Maguire, MD, David M. Brown, MD, Robert Avery, MD, Dante Pieramici, MD, Szilard Kiss, MD, Arshad Khanani, MD, Charles Wykoff, MD Samir Patel, MD, Keunpyo Kim, PhD, Darin Curtiss, PharmD, Stephen Pakola, MD, Sherri Van

Everen, PharmD AAO Retina Subspecialty Days 10/11/2019

Disclosures Research grants: Aerie, Aerpio, Apellis, Clearside, Daiichi,

Genentech/Roche, Graybug, Gyroscope, Hemera, Janssen R&D, KalVista, Kanghong, Novartis, Ophthotech, Optos, Optovue, Regeneron, Regenxbio, Stealth Biotherapeutics, Thrombogenics, Tyrogenex Scientific Advisor: 4DMT, Adverum, Aerie, Aerpio,

Aldeyra, Alkahest, Allegro, Allergan, Annexon, Apellis, Array, Asclepix, Eloxx, Galimedix, Genentech/Roche, Generation Bio, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong, Kodiak, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocugenix,

Ocular Therapeutix, Omeicos, Orbit/Gyroscope, Regeneron, Regenxbio, Retrotope, Santen, Scifluor, Shire, Stealth Biotherapeutics, Takeda, Voyant Board of Directors: Ocular Therapeutix Equity: Adverum, Aldeyra, Allegro, jCyte, and Ocular Therapeutix

2Disclosures Research grants: Aerie, Aerpio, Apellis, Clearside, Daiichi, Genentech/Roche, Graybug, Gyroscope, Hemera, Janssen R&D, KalVista, Kanghong, Novartis, Ophthotech, Optos, Optovue, Regeneron, Regenxbio, Stealth Biotherapeutics,

Thrombogenics, Tyrogenex Scientific Advisor: 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Alkahest, Allegro, Allergan, Annexon, Apellis, Array, Asclepix, Eloxx, Galimedix, Genentech/Roche, Generation Bio, Interface, iRenix, Janssen R&D, jCyte, Kala,

Kanghong, Kodiak, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocugenix, Ocular Therapeutix, Omeicos, Orbit/Gyroscope, Regeneron, Regenxbio, Retrotope, Santen, Scifluor, Shire, Stealth Biotherapeutics, Takeda, Voyant Board of Directors: Ocular

Therapeutix Equity: Adverum, Aldeyra, Allegro, jCyte, and Ocular Therapeutix 2

RGX-314 Uses a Novel AAV8 Vector to Deliver an anti-VEGF Fab Gene

Encoding NAV AAV8 Vector for anti-VEGF fab Cell AAV8 AAV2 anti-VEGF fab RPE Protein RNA Nucleus 1 More Efficient Gene Delivery to the RPE RGX-314 is Designed to Deliver a Gene Encoding for an anti-VEGF fab Protein 1. Vandenberghe et al. 2011 Science

Translational Medicine 3RGX-314 Uses a Novel AAV8 Vector to Deliver an anti-VEGF Fab Gene Encoding NAV AAV8 Vector for anti-VEGF fab Cell AAV8 AAV2 anti-VEGF fab RPE Protein RNA Nucleus 1 More Efficient Gene Delivery to the RPE RGX-314 is Designed

to Deliver a Gene Encoding for an anti-VEGF fab Protein 1. Vandenberghe et al. 2011 Science Translational Medicine 3

RGX-314 Phase I/IIa wAMD Study Has Fully Enrolled 5 Dose Cohorts

Baseline assessment Treatment evaluation Follow up anti-VEGF SD-OCT Anti-VEGF PRN Rescue Injection Criteria injection assessment 0 1 2 6 10 14 18 22 26 54 106 Weeks RGX-314 Safety endpoint administration Secondary endpoints

Previously Treated Subjects Requiring Frequent Injections Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 n = 6 n = 6 n = 6 n = 12 n = 12 Safety Safety Safety Safety 9 1 10 1 10 1 11 1 11 3x10 GC/eye review 1x10 GC/eye review 6x10 GC/eye review 1.6x10 GC/eye

review 2.5x10 GC/eye Subretinal Dosing Completed in 42 Subjects Across Five Dose Cohorts 1. Dose escalation safety review to occur four weeks after final subject in each cohort has been dosed SD-OCT = spectral domain optical coherence tomography

4RGX-314 Phase I/IIa wAMD Study Has Fully Enrolled 5 Dose Cohorts Baseline assessment Treatment evaluation Follow up anti-VEGF SD-OCT Anti-VEGF PRN Rescue Injection Criteria injection assessment 0 1 2 6 10 14 18 22 26 54 106 Weeks

RGX-314 Safety endpoint administration Secondary endpoints Previously Treated Subjects Requiring Frequent Injections Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 n = 6 n = 6 n = 6 n = 12 n = 12 Safety Safety Safety Safety 9 1 10 1 10 1 11 1 11 3x10

GC/eye review 1x10 GC/eye review 6x10 GC/eye review 1.6x10 GC/eye review 2.5x10 GC/eye Subretinal Dosing Completed in 42 Subjects Across Five Dose Cohorts 1. Dose escalation safety review to occur four weeks after final subject in each cohort has

been dosed SD-OCT = spectral domain optical coherence tomography 4

Anti-VEGF Retreatment Allowed for Any Fluid or Disease Activity

Anti-VEGF may be given beginning 4 weeks post-treatment and PRN every 4 weeks thereafter per investigator's discretion if one or more of the criteria apply: CNV-related Vision loss of 5 increased, New ocular letters associated w/ new,

or persistent hemorrhage fluid fluid 5Anti-VEGF Retreatment Allowed for Any Fluid or Disease Activity Anti-VEGF may be given beginning 4 weeks post-treatment and PRN every 4 weeks thereafter per investigator's discretion if one or more of the

criteria apply: CNV-related Vision loss of 5 increased, New ocular letters associated w/ new, or persistent hemorrhage fluid fluid 5

Subjects Enrolled in the Phase I/IIa Trial Were Chronically Treated

Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Total Variable (n=6) (n=6) (n=6) (n=12) (n=12) (n=42) Mean Age (Years) 78.2 78.0 80.0 80.3 81.6 80.0 Baseline BCVA 53.7 50.7 54.7 61.3 54.3 55.7 (Snellen equivalents) (20/100) (20/100) (20/80) (20/63)

(20/80) (20/80) Baseline OCT 361.7 413.2 359.8 411.3 418.3 399.1 (reading center) (n=6) (n=6) (n=6) (n=12) (n=12) (n=42) Baseline serum AAV8 2 (33.3%) 3 (50.0%) 4 (66.7%) 4 (33.3%) 5 (41.7%) 18 (42.9%) Nab+ with titer >1:10 (%) Months Since First

53.5 59.3 71.7 58.1 45.9 56.1 anti-VEGF Injection # Injections 40.7 32.5 34.2 35.7 26.7 33.1 Since Diagnosis (Mean) Average Annualized 9.6 10.5 6.8 10.2 9.9 9.6 Injections Prior to Entry 6 PRIOR THERAPY BASELINE Subjects Enrolled in the Phase I/IIa

Trial Were Chronically Treated Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Total Variable (n=6) (n=6) (n=6) (n=12) (n=12) (n=42) Mean Age (Years) 78.2 78.0 80.0 80.3 81.6 80.0 Baseline BCVA 53.7 50.7 54.7 61.3 54.3 55.7 (Snellen equivalents)

(20/100) (20/100) (20/80) (20/63) (20/80) (20/80) Baseline OCT 361.7 413.2 359.8 411.3 418.3 399.1 (reading center) (n=6) (n=6) (n=6) (n=12) (n=12) (n=42) Baseline serum AAV8 2 (33.3%) 3 (50.0%) 4 (66.7%) 4 (33.3%) 5 (41.7%) 18 (42.9%) Nab+ with

titer >1:10 (%) Months Since First 53.5 59.3 71.7 58.1 45.9 56.1 anti-VEGF Injection # Injections 40.7 32.5 34.2 35.7 26.7 33.1 Since Diagnosis (Mean) Average Annualized 9.6 10.5 6.8 10.2 9.9 9.6 Injections Prior to Entry 6 PRIOR THERAPY BASELINE

RGX-314 Has Been Well Tolerated in All Cohorts RGX-314 was

well-tolerated (n=42) No drug-related SAEs Most AEs were assessed as mild (Grade 1 - 79%) No observed clinically determined immune responses, drug-related ocular inflammation, or any post-surgical inflammation beyond

what is expected following routine vitrectomy Fifteen SAEs that were not drug-related were reported in nine subjects - Two deaths unrelated to RGX-314 - Two ocular procedure-related SAEs: peripheral retinal detachment which was

repaired and an endophthalmitis post aqueous sample collection * Data cut October 9, 2019 7RGX-314 Has Been Well Tolerated in All Cohorts RGX-314 was well-tolerated (n=42) No drug-related SAEs Most AEs were assessed

as mild (Grade 1 - 79%) No observed clinically determined immune responses, drug-related ocular inflammation, or any post-surgical inflammation beyond what is expected following routine vitrectomy Fifteen SAEs that were not

drug-related were reported in nine subjects - Two deaths unrelated to RGX-314 - Two ocular procedure-related SAEs: peripheral retinal detachment which was repaired and an endophthalmitis post aqueous sample collection * Data cut October

Dose Dependent Increase in RGX-314 Protein Observed Across Cohorts As

Measured from Aqueous Samples by ECL 1 Month post-RGX-314 500 376.0 ng/ml 400 2 249.4 ng/ml 160.2 ng/ml 300 200 100 12.8 ng/ml 2.5 ng/ml 0 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 9 10 10 11 11 3 x 10 GC/eye 1 x 10 GC/eye 6 x 10 GC/eye 1.6 x 10

GC/eye 2.5 x 10 GC/eye 1 n=5 n=6 n=6 n=12 n=12 RGX-314 Dose 1. N=5; one subject in Cohort 1 did not have aqueous sample taken at Week 6 2. One subject's protein concentration measured at Day 17 post RGX-314 administration (no 4 week

sample available) 8 Mean RGX-314 Protein (ng/mL)Dose Dependent Increase in RGX-314 Protein Observed Across Cohorts As Measured from Aqueous Samples by ECL 1 Month post-RGX-314 500 376.0 ng/ml 400 2 249.4 ng/ml 160.2 ng/ml 300 200 100 12.8

ng/ml 2.5 ng/ml 0 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 9 10 10 11 11 3 x 10 GC/eye 1 x 10 GC/eye 6 x 10 GC/eye 1.6 x 10 GC/eye 2.5 x 10 GC/eye 1 n=5 n=6 n=6 n=12 n=12 RGX-314 Dose 1. N=5; one subject in Cohort 1 did not have aqueous

sample taken at Week 6 2. One subject's protein concentration measured at Day 17 post RGX-314 administration (no 4 week sample available) 8 Mean RGX-314 Protein (ng/mL)

Cohort 3: Sustained Visual and Anatomic Outcomes over 1.5 years Best

Corrected Visual Acuity (BCVA) 70 70 70 +1 letters 60 60 60 -9 letters 50 +9 letters 50 50 40 40 40 30 30 30 Time Time Time Central Retinal Thickness (CRT) on Heidelberg SD-OCT 600 600 600 +45 m 500 500 500 -26 m 400 400 400 -40 m

300 300 300 200 200 200 Time Time Time 2.6 Injections (annualized) 10.5 Injections (annualized) 9.0 Injections (annualized) 1 Cohort 1 Cohort 2 Cohort 3 1. One subject in Cohort 1 discontinued from the study at four months with four injections and

was imputed as requiring one injection per every 4 weeks visit. 9 m Letters Read D1 D1 M1 M1 M6 M6 1 Yr 1 Yr 1.5 Yrs 1.5 Yrs m Letters Read D1 D1 M1 M1 M6 M6 1 Yr 1 Yr 1.5 Yrs 1.5 Yrs m Letters Read D1 D1 M1 M1 M6 M6 1 Yr 1 Yr 1.5

1.5 Yrs YrsCohort 3: Sustained Visual and Anatomic Outcomes over 1.5 years Best Corrected Visual Acuity (BCVA) 70 70 70 +1 letters 60 60 60 -9 letters 50 +9 letters 50 50 40 40 40 30 30 30 Time Time Time Central Retinal Thickness (CRT) on Heidelberg

SD-OCT 600 600 600 +45 m 500 500 500 -26 m 400 400 400 -40 m 300 300 300 200 200 200 Time Time Time 2.6 Injections (annualized) 10.5 Injections (annualized) 9.0 Injections (annualized) 1 Cohort 1 Cohort 2 Cohort 3 1. One subject in

Cohort 1 discontinued from the study at four months with four injections and was imputed as requiring one injection per every 4 weeks visit. 9 m Letters Read D1 D1 M1 M1 M6 M6 1 Yr 1 Yr 1.5 Yrs 1.5 Yrs m Letters Read D1 D1 M1 M1 M6 M6 1

Yr 1 Yr 1.5 Yrs 1.5 Yrs m Letters Read D1 D1 M1 M1 M6 M6 1 Yr 1 Yr 1.5 1.5 Yrs Yrs

Cohort 3: Injection-free Subjects Continue to Do Well Over 1.5 Years

Anti-VEGF Injection-free Subjects (n= 3 of 6) Sustained RGX-314 Protein Levels Over 1 Year Best Corrected Visual Acuity (BCVA) +11 letters 70 1000 274.9 260.5 236.2 60 ng/ml ng/ml ng/ml 50 40 D1 M1 M6 1 Yr 1.5 100 Yrs Time Central Retinal Thickness

(CRT) on Heidelberg SD-OCT 400 -21 m 10 300 200 100 D1 M1 M6 1 Yr 1.5 1 Yrs Time Month 1 Month 6 1 Year 10 Mean RGX-314 Protein (ng/mL) (log scale) m Letters ReadCohort 3: Injection-free Subjects Continue to Do Well Over 1.5 Years

Anti-VEGF Injection-free Subjects (n= 3 of 6) Sustained RGX-314 Protein Levels Over 1 Year Best Corrected Visual Acuity (BCVA) +11 letters 70 1000 274.9 260.5 236.2 60 ng/ml ng/ml ng/ml 50 40 D1 M1 M6 1 Yr 1.5 100 Yrs Time Central Retinal Thickness

(CRT) on Heidelberg SD-OCT 400 -21 m 10 300 200 100 D1 M1 M6 1 Yr 1.5 1 Yrs Time Month 1 Month 6 1 Year 10 Mean RGX-314 Protein (ng/mL) (log scale) m Letters Read

Cohort 4: Visual and Anatomic Outcomes Best Corrected Visual Acuity

(BCVA) 80 Stable to improved vision and OCT +2 Letters 70 on average 60 50 42% (5 of 12) injection-free at 6 40 months D1 M1 M2 M3 M4 M5 M6 Time 2 patients with incomplete response Central Retinal Thickness (CRT) on Heidelberg

SD-OCT* to anti-VEGF receiving monthly 600 injections 500 -42 m 400 300 200 D1 M1 M2 M3 M4 M5 M6 Time 2.2 inj / 6 mo Cohort 4 (n=12) SD-OCT data read by a central reading center (Duke Reading Center). 11 m Letters ReadCohort 4:

Visual and Anatomic Outcomes Best Corrected Visual Acuity (BCVA) 80 Stable to improved vision and OCT +2 Letters 70 on average 60 50 42% (5 of 12) injection-free at 6 40 months D1 M1 M2 M3 M4 M5 M6 Time 2 patients with

incomplete response Central Retinal Thickness (CRT) on Heidelberg SD-OCT* to anti-VEGF receiving monthly 600 injections 500 -42 m 400 300 200 D1 M1 M2 M3 M4 M5 M6 Time 2.2 inj / 6 mo Cohort 4 (n=12) SD-OCT data read by a central reading

center (Duke Reading Center). 11 m Letters Read

Cohort 5: Visual and Anatomic Outcomes Best Corrected Visual Acuity

(BCVA) 80 Stable to improved vision and OCT +4 Letters 70 on average 60 50 75% (9 of 12) injection free at 5-6 40 months D1 M1 M2 M3 M4 M5 M6 Time Highest clinical response observed Central Retinal Thickness (CRT) on Heidelberg

SD-OCT* 600 500 400 300 -68 m 200 D1 M1 M2 M3 M4 M5 M6 Time 0.8 inj / 5 - 6 mo Cohort 5 SD-OCT data read by a central reading center (Duke Reading Center). 12 1 subject discontinued after 4 months m Letters ReadCohort 5:

Visual and Anatomic Outcomes Best Corrected Visual Acuity (BCVA) 80 Stable to improved vision and OCT +4 Letters 70 on average 60 50 75% (9 of 12) injection free at 5-6 40 months D1 M1 M2 M3 M4 M5 M6 Time Highest clinical

response observed Central Retinal Thickness (CRT) on Heidelberg SD-OCT* 600 500 400 300 -68 m 200 D1 M1 M2 M3 M4 M5 M6 Time 0.8 inj / 5 - 6 mo Cohort 5 SD-OCT data read by a central reading center (Duke Reading Center). 12 1

subject discontinued after 4 months m Letters Read

Cohort 4 and Cohort 5: Anti-VEGF Injection-free Subjects Best Corrected

Visual Acuity (BCVA) 80 80 +5 Letters +2 Letters 70 70 60 60 50 50 40 40 D1 M1 M2 M3 M4 M5 M6 D1 M1 M2 M3 M4 M5 M6 Time Time Central Retinal Thickness (CRT) on Heidelberg SD-OCT* 600 600 500 500 -80 m -61 m 400 400 300 300 200 200 D1 M1

M2 M3 M4 M5 M6 D1 M1 M2 M3 M4 M5 M6 Time Time 0 Injections 0 Injections Cohort 4 (n=5) 42% Cohort 5 (n=9) 75% SD-OCT data read by a central reading center (Duke Reading Center). 13 m Letters Read m Letters ReadCohort 4 and Cohort

5: Anti-VEGF Injection-free Subjects Best Corrected Visual Acuity (BCVA) 80 80 +5 Letters +2 Letters 70 70 60 60 50 50 40 40 D1 M1 M2 M3 M4 M5 M6 D1 M1 M2 M3 M4 M5 M6 Time Time Central Retinal Thickness (CRT) on Heidelberg SD-OCT* 600 600 500 500

-80 m -61 m 400 400 300 300 200 200 D1 M1 M2 M3 M4 M5 M6 D1 M1 M2 M3 M4 M5 M6 Time Time 0 Injections 0 Injections Cohort 4 (n=5) 42% Cohort 5 (n=9) 75% SD-OCT data read by a central reading center (Duke Reading Center). 13 m

Letters Read m Letters Read

Cohort 5: Injections Pre and Post RGX-314 (n=12) 1 2 3 4 5 6 7 8 9 10

11 12 1 Year 0 Month Month Month Month Month Month Time prior to treatment with RGX-314 1 2 3 4 5 6 RGX-314 (n=12) (n=11) (n=5) Months since RGX-314 AFLIBERCEPT BEVACIZUMAB Visit With No Injection RANIBIZUMAB Subject #1 discontinued after 4

months * Data cut October 9, 2019 14 SubjectCohort 5: Injections Pre and Post RGX-314 (n=12) 1 2 3 4 5 6 7 8 9 10 11 12 1 Year 0 Month Month Month Month Month Month Time prior to treatment with RGX-314 1 2 3 4 5 6 RGX-314 (n=12) (n=11) (n=5) Months

since RGX-314 AFLIBERCEPT BEVACIZUMAB Visit With No Injection RANIBIZUMAB Subject #1 discontinued after 4 months * Data cut October 9, 2019 14 Subject

Cohort 5 11 2.5x10 GC/eye Case A: Subject History Prior to RGX-314

09MAY2018 08AUG2018 31OCT2018 30JAN2019 06JUN2018 05SEP2018 05DEC2018 27FEB2019 11JUL2018 03OCT2018 02JAN2019 27MAR2019 15Cohort 5 11 2.5x10 GC/eye Case A: Subject History Prior to RGX-314 09MAY2018 08AUG2018 31OCT2018 30JAN2019 06JUN2018 05SEP2018

05DEC2018 27FEB2019 11JUL2018 03OCT2018 02JAN2019 27MAR2019 15

Cohort 5 Day 1 - VA 73 letters 1 Month 4 Months 11 2.5x10 GC/eye

Case A: 13 Injections in Year Prior with 0 Rescue Injections after Week 1 - OCT response 2 Months 5 Months - VA 75 (+2 letters) RGX-314 Age: 87 Total prior anti-VEGF hx: 40 Last year anti-VEGF: 13 Rescue Inj in Study: 0 RGX-314 1 Week

post-RGX-314 3 Months Week 26 - xx letters 16Cohort 5 Day 1 - VA 73 letters 1 Month 4 Months 11 2.5x10 GC/eye Case A: 13 Injections in Year Prior with 0 Rescue Injections after Week 1 - OCT response 2 Months 5 Months - VA 75

(+2 letters) RGX-314 Age: 87 Total prior anti-VEGF hx: 40 Last year anti-VEGF: 13 Rescue Inj in Study: 0 RGX-314 1 Week post-RGX-314 3 Months Week 26 - xx letters 16

Cohort 5 Day 1 - VA 46 letters (20/125) 1 Month 4 Months 11

2.5x10 GC/eye Case B: 8 Injections in Year Prior with 0 Rescue Injections after Week 1 - OCT response 2 Months 5 Months RGX-314 Age: 86 Total prior anti-VEGF hx: 20 Last year anti-VEGF: 8 Rescue Inj in Study: 0 RGX-314 Week 1 post-RGX-314 3

Months 6 Months - VA 48 (+2 letters) 17Cohort 5 Day 1 - VA 46 letters (20/125) 1 Month 4 Months 11 2.5x10 GC/eye Case B: 8 Injections in Year Prior with 0 Rescue Injections after Week 1 - OCT response 2 Months 5 Months RGX-314 Age:

86 Total prior anti-VEGF hx: 20 Last year anti-VEGF: 8 Rescue Inj in Study: 0 RGX-314 Week 1 post-RGX-314 3 Months 6 Months - VA 48 (+2 letters) 17

RGX-314 Program Next Steps wAMD moving Diabetic to Phase IIb

Retinopathy Study by the IND by end of the year end of the year RGX-314 Gene Therapy Expanding to evaluate SCS delivery using Clearside's proprietary, in-office SCS Microinjector 18RGX-314 Program Next Steps wAMD moving Diabetic to

Phase IIb Retinopathy Study by the IND by end of the year end of the year RGX-314 Gene Therapy Expanding to evaluate SCS delivery using Clearside's proprietary, in-office SCS Microinjector 18

Key takeaways from the RGX-314 Phase I/IIa wAMD Clinical Trial

RGX-314 Phase I/IIa wAMD study has fully enrolled 42 patients in 5 dose cohorts Patients enrolled were severe wAMD requiring frequent anti-VEGF injections Subretinal RGX-314 was well tolerated in 5 dose Cohorts Dose dependent

increase in ocular protein observed across cohorts Cohort 3: subjects continue to demonstrate good vision and anatomic outcomes over 1.5 years Cohort 4: reduction in injection burden with stable to improved anatomic and visual outcomes

Cohort 5: highest clinical response observed with 75% of subjects injection-free with stable to improved anatomic and visual outcomes* RGX-314 moving into Phase IIb trial for wet AMD, Phase II diabetic retinopathy trial, TM and